Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
HIV Unit, Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
Clin Microbiol Infect. 2021 Aug;27(8):1171.e1-1171.e7. doi: 10.1016/j.cmi.2020.09.053. Epub 2020 Oct 16.
The World Health Organization recommends routinely screening HIV-infected patients with CD4 T-cell counts <100/μL for cryptococcal infection to prevent cryptococcal meningitis (CM), based on studies in Sub-Saharan Africa where the prevalence of positive cryptococcal antigen (CrAg+) is ≥ 3% in this subgroup. Data about such prevalence in Spain are unavailable and rare in other European countries. Thus, the Spanish AIDS Study Group guidelines do not recommend routinely screening. We aim to determine the prevalence and outcomes of cryptococcal infection in this subgroup of patients in Spain.
We determined CrAg using a lateral flow assay in banked plasma from participants in the cohort of the Spanish AIDS Research Network. Eligible patients had CD4 T-cell counts ≤100/μL at the time of plasma collection and a follow-up >4 weeks, unless they died.
We included 576 patients from June 2004 to December 2017. Of these, 43 were CrAg+ for an overall prevalence of 7.5%. There were no differences depending on birthplace. The CrAg+ was independently associated with a higher mortality at eight weeks (hazard ratio (HR) 5.36, 95% confidence interval (CI) 1.46-19.56) and 6 months (HR 3.12, 95% CI 1.19-8.21). CM was reported in 10 of the 43 CrAg+ patients. There were no cases among negatives. Five patients had CM when the plasma was collected and five developed it during the follow-up. The number of subjects needed to screen to anticipate the diagnosis of one CM case was 114.
The CrAg+ prevalence among HIV-infected patients with CD4 T-cell counts ≤100/μL diagnosed in Spain, both immigrants and native-born Spanish, is >7%. Consequently, the Spanish AIDS Study Group guidelines have to be updated and recommend routine screening for cryptococcal infection in these patients. Future studies should explore whether this recommendation could be firmly applied to other European populations.
世界卫生组织建议,对 CD4 细胞计数<100/μL 的 HIV 感染者常规进行隐球菌感染筛查,以预防隐球菌脑膜炎(CM),这一建议基于撒哈拉以南非洲的研究,在该地区,这一亚组中阳性隐球菌抗原(CrAg+)的患病率≥3%。关于西班牙这一患病率的数据尚未可知,在其他欧洲国家也很少见。因此,西班牙艾滋病研究小组的指南不建议常规筛查。我们旨在确定西班牙这组患者中隐球菌感染的患病率和结局。
我们使用西班牙艾滋病研究网络队列中保存的血浆进行侧向流检测来确定 CrAg。符合条件的患者在采集血浆时的 CD4 细胞计数≤100/μL,且随访时间>4 周,除非他们死亡。
我们纳入了 2004 年 6 月至 2017 年 12 月期间的 576 名患者。其中 43 名患者 CrAg+,总体患病率为 7.5%。出生地无差异。CrAg+与 8 周时(危险比(HR)5.36,95%置信区间(CI)1.46-19.56)和 6 个月时(HR 3.12,95% CI 1.19-8.21)较高的死亡率独立相关。在 43 例 CrAg+患者中报告了 10 例 CM。CrAg-患者无一例发生 CM。有 5 例患者在采集血浆时患有 CM,有 5 例患者在随访期间发生了 CM。筛查预测 1 例 CM 病例所需的受试者数量为 114 例。
在西班牙诊断的 CD4 细胞计数≤100/μL 的 HIV 感染者中,CrAg+的患病率(包括移民和土生土长的西班牙人)>7%。因此,西班牙艾滋病研究小组的指南必须更新,并建议对这些患者常规筛查隐球菌感染。未来的研究应探讨这一建议是否可以坚定地应用于其他欧洲人群。